Epstein-Barr Virus Infections
2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Cell Therapy
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Angeles TherapeuticsCA - Los Angeles
1 program1
cytotoxic t-lymphocytesPhase 22 trials
Active Trials
NCT01945619No Longer Available
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Angeles Therapeuticscytotoxic t-lymphocytes
Clinical Trials (2)
Total enrollment: 20 patients across 2 trials
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
Start: Jul 2020Est. completion: Dec 202720 patients
Phase 2Recruiting
Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
N/ANo Longer Available
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 20 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.